Question 1

What is Kalios Peptides?

Accepted Answer

Kalios is an independent reference database for peptide compounds. Every profile covers mechanism of action, clinical evidence, FDA status, and the honest limitations most sources skip. The site covers 149 peptide compounds and 7 stacks, three tools (a vial-to-syringe calculator, COA Check for lab reports and the stack receipt) and an FDA PCAC 2026 review tracker. No paywall, no sales, no partner clinics.

Question 2

Is Kalios independent and free?

Accepted Answer

Yes. Kalios takes no money from compounding pharmacies, peptide vendors, sponsors, or affiliate programs. There is no paywall and no email gate. The site is supported solely by its independent author. Its position on every compound — including the PCAC 2026 review compounds — is neutral and based on published primary sources.

Question 3

How many peptide compounds does Kalios cover?

Accepted Answer

149 peptide compounds with full profiles, plus 7 stacks (Wolverine, KLOW, Glow, GH, Mito, Flow State, Tesa/Ipa) and the stack receipt, which looks up any two of 148 compounds: what has been tested together in people, usually nothing (38 pairs a published study gave to people together, 21 of them with a page of their own). Every profile follows a fixed 17-section template covering quick facts, mechanism, evidence, human data, dosing, reconstitution, side effects, monitoring, stacking, regulatory status, and 15+ verified primary references.

Question 4

What is the FDA PCAC 2026 peptide review?

Accepted Answer

FDA's Pharmacy Compounding Advisory Committee (PCAC) is reviewing 12 peptides for possible inclusion on the Section 503A Bulk Drug Substances List. It voted on seven of them on July 23-24, 2026: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon. The other five (GHK-Cu, Melanotan II, LL-37, dihexa acetate and PEG-MGF) are scheduled for a PCAC meeting before the end of February 2027. A PCAC vote is advisory, so none of the 12 is legal to compound today. Vote counts and FDA's next steps are on the Kalios FDA PCAC 2026 tracker.

Peptides for regular people.